Tag: ACHL
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
– Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 – – Strong cash position of $158.5 million supports operations into mid-2025 – LONDON, May 10, 2023 (GLOBE NEWSWIRE) —Achilles Therapeutics plc (NASDAQ:…
Investegate |Achilles Therapeutics PLC Announcements
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status – Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor – – Patent applies to any…
